Frontlight ResearchEarly access
TerminatedPhase 1
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Finland, Germany, Israel, Japan, Singapore, South Korea, and Spain8 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 25 people enrolled
- Started
- 7 Sept 2020
- Ended
- 5 Sept 2024
- Type of study
- Interventional
- Treatments tested
- JBH492
- Record updated
- 10 October 2025
- Why it stopped
- Business, strategic, and development considerations and not due to any safety concerns
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- For patients with CLL:
- Confirmed diagnosis of chronic lymphocytic leukemia (CLL); For patients with NHL:
- Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL)
- Must have a site of disease amenable to biopsy, and be suitable and willing to undergo study required biopsies at screening and during therapy
Who cannot take part
- Any prior history of treatment with maytansine (DM1 or DM4)-based ADC
- Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was completed >4 weeks before first dose of study treatment. Patients that have been effectively treated for CNS disease and are stable under systemic therapy may be enrolled provided all other inclusion and exclusion criteria are met. Patients who received prophylactic intrathecal treatment are eligible, if treatment discontinued >5 half-lives prior to the first dose of study treatment
- History of anaphylactic or other severe hypersensitivity/infusion reactions to ADCs, monoclonal antibodies (mAbs) and/or their excipients such that the patient in unable to tolerate immunoglobulin/monoclonal antibody administration
- Patients with any active or chronic corneal disorders
- Patients who have any other condition that precludes monitoring of the retina or fundus
- Impaired cardiac function or clinically significant cardiac disease
- Known history of Human Immunodeficiency Virus (HIV) infection
- Active HBV or HCV infection. Patients whose disease is controlled under antiviral therapy should not be excluded. Patients who are anti-HBcAb positive should be HBsAg negative and HBV-DNA negative to be eligible; Other inclusion and exclusion criteria may apply
- Known intolerance to a maytansinoid
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the First-In-Human study was to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.
The group in the trial
- JBH492 single agentTreatment being tested
Patients with R/R CLL or NHL
Treatment: JBH492
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
- Record updated
- 10 October 2025